An integrin antagonist (MK-0429) decreases proteinuria and renal fibrosis in the ZSF1 rat diabetic nephropathy model-Reference-Cited by-同舟云学术

An integrin antagonist (MK-0429) decreases proteinuria and renal fibrosis in the ZSF1 rat diabetic nephropathy model

Published:2017-09-11 Issue:5 Volume:5 Page:e00354
ISSN:2052-1707
Container-title:Pharmacology Research & Perspectives
language:en
Short-container-title:Pharmacol Res Perspect

Author:

Zhou Xiaoyan¹^ORCID,Zhang Ji²,Haimbach Robin²,Zhu Wei²,Mayer-Ezell Rosemary¹,Garcia-Calvo Margarita¹,Smith Elizabeth¹,Price Olga¹,Kan Yanqing²,Zycband Emanuel²,Zhu Yonghua²,Hoek Maarten²,Cox Jason M.³,Ma Lijun²,Kelley David E.²,Pinto Shirly²

Affiliation:

1. Department of Pharmacology; Merck & Co., Inc.; 2000 Galloping Hill Road Kenilworth New Jersey 07033

2. Department of Cardiometabolic Diseases; Merck & Co., Inc.; 2000 Galloping Hill Road Kenilworth New Jersey 07033

3. Department of Medicinal Chemistry; Merck & Co., Inc.; 2000 Galloping Hill Road Kenilworth New Jersey 07033

Funder

Merck

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,Neurology

Reference41 articles.

1. Kidney disease and increased mortality risk in type 2 diabetes;Afkarian;J Am Soc Nephrol,2013

2. Targeting the TGFβ signaling pathway in disease;Akhurst;Nat Rev Drug Discov,2012

3. Molecular mechanisms in the pathogenesis of diabetic nephropathy: an update;Arora;Vascul Pharmacol,2013

4. A soluble guanylate cyclase activator inhibits the progression of diabetic nephropathy in the ZSF1 rat;Boustany-Kari;J Pharmacol Exp Ther,2016

5. The next generation of therapeutics for chronic kidney disease;Breyer;Nat Rev Drug Discov,2016

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IGFBP2 induces podocyte apoptosis promoted by mitochondrial damage via integrin α5/FAK in diabetic kidney disease;Apoptosis;2024-05-25

2. A modest proposal: targeting αv integrin-mediated activation of latent TGFbeta as a novel therapeutic approach to treat scleroderma fibrosis;Expert Opinion on Investigational Drugs;2024-02-26

3. Potential therapeutic medicines for renal fibrosis: Small-molecule compounds and natural products;Bioorganic Chemistry;2024-02

4. Obstructive nephropathy and molecular pathophysiology of renal interstitial fibrosis;Physiological Reviews;2023-10-01

5. Small Molecules against Metastatic Tumors: Concrete Perspectives and Shattered Dreams;Cancers;2023-08-18